Clearside Biomedi (CLSD) Stock Price, Quote & News

Company Profile

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch...

Industry: Biotechnology

Sector: Healthcare

Phone: 678 270 3631

Fax: 678 270 4033

Website: clearsidebio.com

Address:

900 North Point Parkway, Suite 200, Alpharetta, United States

Thespartantrade Oct. 7 at 8:25 AM

$SDOT $CLSD $BDSX $STKH Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.

0 · Reply

cheapwin Oct. 6 at 5:33 PM

$CLSD 8

0 · Reply

6monthinvester Oct. 6 at 3:53 AM

$CLSD good growth but negative revenue

0 · Reply

Dasmin Oct. 3 at 10:48 PM

$CLSD What are the chances we hear back before Christmas?

0 · Reply

Vikingsstrade Oct. 3 at 5:35 PM

0 · Reply

RipNLoad Oct. 3 at 4:33 PM

$CLSD back in with a nice position! somethings cooking...

0 · Reply

cheapwin Oct. 2 at 5:44 PM

$CLSD Buyout imminent. All telltale signs point to one.

2 · Reply

maphere Oct. 2 at 4:06 PM

$CLSD And another who took the banner down got a new job elsewhere: https://www.linkedin.com/posts/angela-rea-ramsey-mba-45b4b594_im-happy-to-share-that-im-starting-a-new-ugcPost-7379513223244357632-qJ_I?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAFbX6sB6O9p99YHD4xHsIXTcY3tswQnStc

1 · Reply

rando321456 Oct. 1 at 8:07 PM

$CLSD As annoying as OCUL is we really should be rooting for them imo. If they can actually steal a march on Regeneron and Roche it should open doors for CLS-AX(assuming a deal isn't already done for the asset).

1 · Reply

Turmfalke Oct. 1 at 6:50 PM

$CLSD What Buyout price level was mentioned on CLSD?

1 · Reply

Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress

Jul 23, 2025, 7:05 AM EDT - 2 months ago

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

Jul 17, 2025, 7:05 AM EDT - 2 months ago

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

Jun 17, 2025, 7:05 AM EDT - 3 months ago

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

May 21, 2025, 7:05 AM EDT - 4 months ago

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

May 14, 2025, 4:05 PM EDT - 5 months ago

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025, 7:05 AM EDT - 5 months ago

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

May 8, 2025, 7:05 AM EDT - 5 months ago

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

May 1, 2025, 7:05 AM EDT - 5 months ago

Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference

Apr 1, 2025, 7:05 AM EDT - 6 months ago

Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:31 PM EDT - 6 months ago

Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript

Mar 27, 2025, 4:05 PM EDT - 6 months ago

Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:05 AM EDT - 7 months ago

Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Mar 20, 2025, 7:05 AM EDT - 7 months ago

Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Mar 12, 2025, 7:05 AM EDT - 7 months ago

Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

Mar 6, 2025, 7:05 AM EST - 7 months ago

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Feb 20, 2025, 7:05 AM EST - 8 months ago

Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Feb 10, 2025, 7:05 AM EST - 8 months ago

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

Feb 4, 2025, 7:05 AM EST - 8 months ago

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference

Jan 28, 2025, 7:05 AM EST - 8 months ago

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

Jan 22, 2025, 7:05 AM EST - 9 months ago

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

Dec 19, 2024, 7:05 AM EST - 10 months ago

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

Nov 25, 2024, 7:05 AM EST - 11 months ago

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

Nov 12, 2024, 8:37 PM EST - 11 months ago

Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 9:05 AM EST - 11 months ago

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Nov 6, 2024, 7:05 AM EST - 11 months ago

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Nov 4, 2024, 7:05 AM EST - 1 year ago

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Oct 31, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Oct 22, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Oct 9, 2024, 6:30 AM EDT - 1 year ago

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Aug 27, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 1, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Jul 24, 2024, 11:23 PM EDT - 1 year ago

Clearside Biomedical, Inc. (CLSD) Suprachoroidal Space Drug Delivery (Transcript)

Jul 22, 2024, 12:00 PM EDT - 1 year ago

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

Jul 11, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Jun 27, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

Jun 25, 2024, 12:54 PM EDT - 1 year ago

Why Is Clearside Biomedical Stock Gaining Today?

Jun 12, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

May 21, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

May 9, 2024, 9:14 PM EDT - 1 year ago

Clearside Biomedical, Inc. (CLSD) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 1 year ago

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:15 PM EDT - 1 year ago

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

Apr 16, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Apr 2, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mar 18, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Mar 13, 2024, 12:47 AM EDT - 1 year ago

Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 7:05 AM EST - 1 year ago

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

Thespartantrade Oct. 7 at 8:25 AM

0 · Reply

cheapwin Oct. 6 at 5:33 PM

$CLSD 8

0 · Reply

6monthinvester Oct. 6 at 3:53 AM

$CLSD good growth but negative revenue

0 · Reply

Dasmin Oct. 3 at 10:48 PM

$CLSD What are the chances we hear back before Christmas?

0 · Reply

Vikingsstrade Oct. 3 at 5:35 PM

0 · Reply

RipNLoad Oct. 3 at 4:33 PM

$CLSD back in with a nice position! somethings cooking...

0 · Reply

cheapwin Oct. 2 at 5:44 PM

$CLSD Buyout imminent. All telltale signs point to one.

2 · Reply

maphere Oct. 2 at 4:06 PM

1 · Reply

rando321456 Oct. 1 at 8:07 PM

1 · Reply

Turmfalke Oct. 1 at 6:50 PM

$CLSD What Buyout price level was mentioned on CLSD?

1 · Reply

BioRich Oct. 1 at 2:42 PM

$CLSD still like this one and hope they get the Buyout we have been waiting for. I think it's there, just waiting on the ink to dry. Same with $GUTS, $VERU, $JMIA and $VNDA. Love Buyout season. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers!

3 · Reply

buyandsold Oct. 1 at 12:58 AM

$CLSD rather a volatile banger

0 · Reply

Dasmin Sep. 30 at 10:46 PM

$CLSD How much longer is our wait?

1 · Reply

maphere Sep. 30 at 5:18 PM

$CLSD She got hired so likely took the banner off as she was in discussions: https://www.linkedin.com/posts/angela-r-wright_im-happy-to-share-that-im-starting-a-new-ugcPost-7378629814305574912-PybD?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAFbX6sB6O9p99YHD4xHsIXTcY3tswQnStc

1 · Reply

DeppJones Sep. 30 at 11:23 AM

$CLSD $475 million capital raise by OCUL

1 · Reply

maphere Sep. 29 at 3:42 PM

$CLSD $RGNX In 3 weeks (Oct.18-20) at AAO: Section IX: Late Breaking Developments, Part I Suprachoroidal Surabgene Lomparvovec (Sura-vec, ABBV-RGX-314): First Time 2-Year Results in Non-Proliferative Diabetic Retinopathy Charles C Wykoff, MD, PhD https://aao.apprisor.org/apsSession.cfm?id=RET11

2 · Reply

rando321456 Sep. 29 at 1:51 PM

$CLSD Man imagine how sweet it would be if the Avoralstat read out goes well in a few months(assuming we're in this weird state still).

1 · Reply

maphere Sep. 27 at 5:02 PM

$CLSD New patent extension, link only offers a snippet: Alexandria, Sept. 26 -- Clearside Biomedical Inc has secured a patent on Injectable Triamcinolone Formulations. Nguyen Thai Q, Burke Brian, Lee Edward and Andino Rafael Victor developed the invention. The patent application number is US202017603816 20200416. The patent publication number is US12419833 (B2). International Pate.. https://www.globalipnews.com/?q=clearside

1 · Reply

6monthinvester Sep. 26 at 6:50 PM

$CLSD can be gem

0 · Reply

RedwoodCapitalGroup Sep. 26 at 2:31 PM

$CLSD NXXT risk feels defined while reward is open air above recent highs 🎯 I like that skew for size

0 · Reply

ForkMAN Sep. 26 at 1:51 PM

$CLSD I am in here. $4 looks interesting.

0 · Reply

JaumeIII Sep. 25 at 10:15 AM

$CLSD Do we know for a fact that HCR gave up the 30 million change of control payment? Or is that just an assumption?

1 · Reply

Market Cap	26.06M
Revenue (ttm)	1.66M
Net Income (ttm)	-34.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,069.28%
Debt to Equity Ratio	0.00

Volume	1,351,424
Avg Vol	5,568,396
Day's Range	N/A - N/A
Shares Out	78.51M
Stochastic %K	52%
Beta	2.11
Analysts	Sell
Price Target	$4.00